drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Anti–IL-5Rα monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity to deplete eosinophils and basophils.
nci_thesaurus_concept_id
C88594
nci_thesaurus_preferred_term
Benralizumab
nci_thesaurus_definition
An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.
drug_mesh_term
Benralizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Afucosylated humanized monoclonal antibody targeting IL-5 receptor alpha (IL-5Rα). Binds IL-5Rα on eosinophils and basophils and triggers enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), leading to depletion/apoptosis of these cells and suppression of eosinophilic inflammation.
drug_name
Benralizumab
nct_id_drug_ref
NCT06778746